What does this video actually claim?
KimmiG shares a 12-week update on 5mg Zepbound (tirzepatide) for postpartum weight loss. While the video doesn't make explicit medical claims, the hashtags suggest she's promoting GLP-1 use for weight management after childbirth.
The creator positions herself as a mom in her mid-30s documenting her experience with tirzepatide. Her massive 64.1K views show how hungry people are for real-world GLP-1 experiences.
Without seeing her actual results or claims about effectiveness, we can't verify her specific outcomes. But her dosage and timeline raise some questions worth examining.
Is 5mg the right Zepbound dose at 12 weeks?
She's likely on the wrong dose for that timeframe. The FDA-approved Zepbound escalation schedule starts at 2.5mg for four weeks, then increases to 5mg, 7.5mg, 10mg, and finally 15mg every four weeks.
At 12 weeks, patients should typically be on 10mg, not 5mg. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) that got tirzepatide approved used this escalation pattern for safety reasons.
Either she's behind schedule, experienced side effects requiring a slower increase, or she's not following standard protocols. None of these scenarios are necessarily bad, but they're worth noting for anyone following her journey.
Does tirzepatide work for postpartum weight loss?
The clinical trials didn't specifically study postpartum women, but the drug works regardless of why someone gained weight. SURMOUNT-1 showed 15% body weight reduction at 72 weeks with 10mg tirzepatide versus 3.1% with placebo.
However, postpartum weight loss has unique considerations. Breastfeeding mothers shouldn't use GLP-1 medications since we don't know if they pass into breast milk.
The timing matters too. Many women lose significant pregnancy weight naturally in the first six months postpartum. Starting tirzepatide too early might mean paying $1,000+ monthly for weight loss that would happen anyway.
What are the real risks she's not mentioning?
GLP-1 content creators rarely discuss serious side effects, and this video appears no different. Tirzepatide caused treatment discontinuation in 14.3% of SURMOUNT-1 participants due to adverse events.
The most common issues are gastrointestinal. Nausea hit 31% of patients on 10mg versus 8% on placebo. Diarrhea affected 18% versus 7%. Vomiting occurred in 15% versus 2%.
More concerning are rare but serious risks. Pancreatitis, gallbladder problems, and potential thyroid tumors appeared in animal studies. The FDA requires black box warnings about thyroid C-cell tumors, though human risk remains unclear.
Should you follow her example?
Definitely not without medical supervision. Social media weight loss journeys make terrible medical advice, even when the creator has good intentions.
Tirzepatide requires prescription monitoring for a reason. Doctors need to check kidney function, watch for pancreatitis symptoms, and adjust doses based on individual response and side effects.
If you're interested in GLP-1 medications postpartum, talk to your healthcare provider about timing, especially if you're breastfeeding. The excitement around these drugs is justified, but they're not supplements you can start based on TikTok testimonials.